Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes

• Status: Completed
• Trial end date: 1999-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in Europe. The aim of this trial is to assess the effect of NNC 90-1170 (liraglutide) on pulsatile insulin secretion and insulin secretion after a standard meal in subjects with type 2 diabetes.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Liraglutide

Criteria

Inclusion Criteria:

• Diagnosed with type 2 diabetes, either newly diagnosed with at least two months of diet treatment, or in current OHA (oral hypoglycaemic agent) treatment with stable dose for at least six months

• BMI (Body Mass Index) between 24 and 35 kg/m^2 (both inclusive)

• Fasting plasma glucose between 6 and 15 mmol/l (both inclusive)

• Anti-GAD (glutamic acid decarboxylase) negative

Exclusion Criteria:

• Known or suspected allergy to trial product or related products

• Receipt of any investigational drug within three months prior to this trial

• Recurrent severe hypoglycaemia as judged by the investigator

• Cardiac disease or any clinically significant abnormal ECG (electrocardiogram)

• Use of any drug (except oral hypoglycaemic agents (OHAs)) which in the investigator's opinion could interfere

• with the blood glucose level (i.e., insulin, systemic corticosteroids, thiazides)

• Liver or renal disease